B. Long-acting/Extended-release Opioids

Size: px
Start display at page:

Download "B. Long-acting/Extended-release Opioids"

Transcription

1 4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone or equianalgesic dose of another opioid. Abbreviations: APAP: acetaminophen; ASA: acetylsalicylic acid; CNS: central nervous system; CrCl: creatinine clearance; d: day(s); ER: extended-release; hr: hour(s); IBU: ibuprofen; LOT: long-term opioid therapy; M3G: morphine-3-glucuronide; M6G: morphine-6-glucuronide; MAOIs: monoamine oxidase inhibitors; mg: milligram(s); min: minute(s); ml: milliliter(s); SSRIs: selective serotonin reuptake inhibitors B. Long-acting/Extended-release Opioids Table D-2. Use of Long-acting/Extended-release Opioids in Adults [198] Long-acting/ER opioids expose patients and other users to the risks of opioid misuse and OUD, which can lead to overdose and death, even when used at recommended dosages. Long-acting/ER opioids should be reserved for patients for whom alternative analgesic treatment options (e.g., non-opioid analgesics or immediate-release opioid analgesics) are ineffective, not tolerated, or provide inadequate control of pain. Assess each patient s risk prior to prescribing long-acting/er opioids and institute risk mitigation strategies. The FDA has mandated that long-acting/er opioids be subject to a structured Risk Evaluation and Mitigation Strategy (REMS) program to manage known or potential serious risks associated with their use (see Most abuse deterrent technologies have been designed to make manipulation more difficult or to make abuse of the manipulated product less attractive or less rewarding. In spite of these efforts, no opioid formulation prevents consumption of a large number of intact capsules or tablets, which continues to be the most common method of abuse. Long-acting/ER opioids should not be used for management of acute pain (with exception of oxycodone/acetaminophen ER tablets), as an as-needed medication, or on initiation of LOT (see Recommendation 13). Source: February 2017 Page 88 of 198

2 Buprenorphine buccal film Available in strengths of 75, 150, 300, 450, 600, 750 and 900 mcg/film for twice daily Buprenorphine TDS Available in every 7 day patch formulation that delivers transdermal buprenorphine at the following rates: 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr 75 mcg once or twice daily for at least 4 days, then increase dose to 150 mcg every 12 hr There is potential for buprenorphine to precipitate withdrawal in patients already on opioids; to reduce risk, the dose of other opioid should be tapered to 30 mg MEDD before initiating buprenorphine In opioid-naïve or in patients on <30 mg MEDD of alternate agent: Initiate treatment with 5 mcg/hr patch There is potential for buprenorphine to precipitate withdrawal in patients already on opioids; to reduce risk, the dose of other opioid should be tapered to 30 mg MEDD before initiating buprenorphine; the 10 mcg/hr patch may then be initiated at the next dosing interval After initial dosing, dosing changes as necessary can proceed in increments of 150 mcg every 12 hr, no more frequently than every 4 days Patients on prior dose of opioid 30 to 89 mg MEDD may initiate buprenorphine film at 150 mcg every 12 hr, 90 to 160 mg MEDD may initiate at 300 mcg every 12 hr; if prior opioid is >160 mg MEDD consider an alternative analgesic Time to steady state ~3 days with every 12 hr dosing The maximum dose of buprenorphine TDS 20 mcg/hr may not provide adequate analgesia for patients requiring greater than 80 mg MEDD; an alternate analgesic should be considered Steady state achieved in ~3 days Elderly: Initiation at the low end of the dosing range is recommended Renal dysfunction: No dose adjustment recommended Hepatic dysfunction: Patients with severe hepatic impairment should have starting and titration doses reduced by half that of patients with normal liver function Dosage does not need to be adjusted in patients with mild or moderate hepatic impairment, renal impairment, or in the elderly Potential treatment option for patients with significant renal impairment or those with gastrointestinal structural or functional abnormality that interferes with swallowing or absorption of oral medications QTc prolongation reported with recommended doses of buprenorphine; maximum dose of 900 mcg every 12 hr established due to the potential for this adverse effect; avoid in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic drugs Buprenorphine buccal film is a potential treatment option for patients with significant renal impairment and those with gastrointestinal structural or functional abnormality that interferes with swallowing or absorption of orally administered medications Buprenorphine patch 10 mcg/hr is approximately equivalent to an oral MEDD of mg; the 20 mcg/hr patch is approximately equivalent to a MEDD of mg Dose of one 20 mcg/hr patch per week should not be exceeded due to risk of QTc prolongation Avoid use in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic medications Advise patients that application of external heat (e.g., hot baths, sunbathing, saunas, heating pads) increases maximum plasma concentration of buprenorphine and risk of fatal overdose February 2017 Page 89 of 198

3 Fentanyl TDS Available in every 3 day patch formulation that delivers transdermal fentanyl at the following rates: 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, and 100 mcg/hr Fentanyl TDS is contraindicated in non-opioid-tolerant patients Fentanyl TDS is contraindicated in the management of mild or post-operative pain, and as an as-needed analgesic The initial dose of fentanyl TDS in opioidtolerant patients 2 is 25 mcg/hr, applied every 72 hr; the 12 mcg/hr dose has not been evaluated as an initial dose Fentanyl TDS must be used only on intact skin Dose change increments should be based on supplemental opioid doses, using a ratio of fentanyl TDS 12 mcg/hr for every 45 mg/24 hr of supplemental oral MEDD Dosing changes, as necessary, should occur at least 3 days after the initial dose; thereafter, not more often than every 6 days Elderly: Twice as sensitive to fentanyl as younger patients; avoid initiation at doses >25 mcg/hr unless patient is already taking >135 mg oral morphine or equivalent Hepatic / Renal dysfunction: Reduce dose by 50% in mildmoderate impairment and avoid use if impairment is severe Patients with fever: Increased body temperature may increase release of fentanyl from the TDS; monitor patients for opioid adverse effects and modify dosage as necessary Consider fentanyl TDS in patients with persistent, moderate-tosevere pain who cannot take oral ER morphine or oral ER oxycodone Avoid application of external heat sources (e.g., heating pads, electric blankets, heat lamps, saunas, hot tubs, hot baths, sunbathing, heated water beds) to the application site while the patch is worn as heat may increase release and speed absorption of fentanyl Using damaged or cut fentanyl TDS patches can lead to rapid release of the contents of the patch and fatal overdose Use of fentanyl TDS with CYP3A4 inhibitors 3 can result in increased fentanyl plasma concentrations, increased or prolonged opioid effects, including fatal respiratory depression; use extreme caution and frequent monitoring in patients receiving these combinations CYP 3A4 inducers may increase fentanyl clearance February 2017 Page 90 of 198

4 Hydrocodone ER ER tablets contain 20, 30, 40, 60, 80, 100 or 120 mg hydrocodone for once daily ER capsules contain 10, 15, 20, 30, 40 or 50 mg hydrocodone for every 12 hr 20 mg ER tablet once daily 10 mg ER capsule every 12 hr Opioid tolerant 2 patients: Convert current opioid to equianalgesic daily dose of hydromorphone ER; reduce the calculated amount by 33-50% for initial start dose (see Table D-3) For opioid-experienced, both ER tablets and capsules: Convert current opioid to equianalgesic hydrocodone dose then reduce that dose by 25%; initiate at nearest whole-tablet or capsule strength, rounding down as necessary For both tablets and capsules: Dose change increments of 20 mg per day may be made every 3 to 7 days Steady state achieved in ~3 days of dosing Elderly: No significant pharmacokinetic differences Patients with renal impairment: Hydrocodone plasma concentrations are increased in moderate or severe impairment; use low initial dose and monitor closely for adverse events such as excessive sedation and respiratory depression Patients with hepatic impairment: no dosage adjustment is required in mild or moderate hepatic impairment; start with the lowest dose, 10 mg, in patients with severe hepatic impairment, and monitor closely CYP3A4 inhibitors 3 may decrease clearance of hydrocodone, increase plasma concentrations, and increase risk of overdose; CYP3A4 inducers 4 may increase clearance and reduce opioid effect Both ER tablets and ER capsules are formulated with polyethylene oxide which imparts ER properties Hydrocodone ER tablets or capsules must be swallowed intact and should not be cut, broken, chewed, crushed or dissolved due to risk of fatal overdose ER tablet has abuse deterrent labeling related to resistance to crushing and high viscosity when dissolved in aqueous solution ER capsule has abuse deterrent properties but is not FDA-labeled as an abuse deterrent formulation February 2017 Page 91 of 198

5 Hydromorphone ER Tablets Available as 8, 12, 16, and 32 mg tablets for once daily Not indicated in opioidnaïve patients due to the risk of respiratory depression Opioid tolerant.2 patients: Convert current opioid to equianalgesic daily dose of hydromorphone ER; reduce the calculated amount by 33-50% for initial start dose (see Table D-3) Dosage adjustments may be made in increments of 4 to 8 mg every 3 to 4 days as needed to achieve adequate analgesia Steady state reached after 3 to 4 days of once-daily dosing Elderly: No specific guidance; monitor closely, particularly when initiating or titrating dosage Patients with renal impairment: Start patients with moderate impairment at 50% of usual dose, and patients with severe impairment at 25% of usual dose Patients with hepatic impairment: Start patients with moderate impairment at 25% of usual dose in non-impaired patients Hydromorphone ER tablets must be swallowed intact and should not be cut, broken, chewed, crushed or dissolved due to risk of fatal overdose Hydromorphone ER contains sulfites Hydromorphone ER has abuse deterrent properties but is not FDA-labeled as an abuse deterrent formulation February 2017 Page 92 of 198

6 Dose change increments of 2.5 mg every 8 hr may be made every 5 to 7 days Delayed analgesia or toxicity may occur because of drug accumulation after repeated doses, e.g., on days 2 to 5; if patient has excessive sedation during this timeframe, consider temporarily holding dose(s), lowering the dose, and/or slowing the titration rate Once a stable analgesic dose is reached, the dosing interval may be extended to every 8 to 12 hr or longer Elderly or debilitated: Consider reduced dosing in elderly or debilitated patients who may be more sensitive to opioid adverse effects Hepatic dysfunction: No dosage adjustments required in patients with stable chronic liver disease or mild-to-moderate hepatic dysfunction; avoid in severe liver disease Renal dysfunction: Methadone and its metabolites do not accumulate in patients with renal failure; however, dosage reduction by up to 50-75% is recommended in patients with CrCl <10 ml/min Prescribers of methadone should be thoroughly familiar with its complex pharmacokinetic and pharmacodynamic properties or consult a clinician with experience in dosing methadone Plasma half-life (22 to 128 hr shortterm; 24 to 48 hr at steady-state) may be longer than the analgesic duration Methadone has little crosstolerance with other opioids; therefore, even patients with a high degree of opioid tolerance may be at risk for overdose when switched to methadone Methadone is the only long-acting opioid available as an oral solution Methadone may be subject to drug interactions with agents that can influence CYP2B6 (e.g., ticlopidine) May prolong QTc intervals on ECG; risk of torsade de pointes; see Appendix D for detailed QTc monitoring information Methadone Available as 5 and 10 mg tablets and oral solution, 5 or 10 mg/5 ml, for every 8 to 12 hr Should not be used for as-needed supplemental OT Initial dose: 2.5 to 5 mg orally every 8 to 12 hr; more frequent (every 6 hr) may be necessary during initiation to maintain analgesia START LOW AND GO SLOW See Appendix D for detailed dosing information including dosing recommendations in patients previously exposed to opioids Monitor patients carefully during initiation, conversions to and from other opioids, and dose titration February 2017 Page 93 of 198

7 Morphine CR or SR tablets should be swallowed whole, not broken, chewed, or crushed For patients who have difficulty swallowing, SR and ER capsules may be opened and the pellets may be sprinkled onto a small amount of soft food (for without chewing) or administered via 16F gastrostomy tube Steady state achieved with morphine ER within 24 to 36 hr Information applies to all formulations of morphine listed Elderly: Use with caution and at lower dose Patients with renal dysfunction: Bioavailability is increased and clearance is decreased; metabolites M3G and M6G accumulate significantly Reduce dose or, if severe renal impairment exists, avoid use Patients with hepatic dysfunction: Clearance decreases and half-life increases; M3G and M6G to morphine ratios are reduced; use carefully in patients with cirrhosis and consider reducing dose or extending dosing interval by 1.5 to 2 times Morphine SR is preferred first-line long-acting agent because of similar efficacy to other longacting opioids, comparable safety profile, provider familiarity with use, and lower cost M6G, an active metabolite, may accumulate in renal impairment and contribute to excessive opioid effects M3G, a metabolite without analgesic activity, may accumulate in renal impairment; this metabolite has been implicated in morphine-induced neurotoxicity, hyperalgesia, and allodynia Morphine/naltrexone ER capsule has abuse deterrent labeling related to potential to precipitate withdrawal if drug is taken by other than oral route Morphine CR or SR Available in 15, 30, 60, 100, and 200 mg strengths for every 8 to 12 hr Morphine ER capsules available in 10, 20, 30, 40, 50, 60, 70, 80, 100, 130, 150, and 200 mg capsule strengths for once daily Morphine and Naltrexone ER Capsule Available as 20/0.8, 30/1.2, 50/2, 60/2.4, 80/3.2, and 100/4 capsule strengths (mg morphine/mg naltrexone) for once or twice-daily Morphine CR or SR 15 mg every 8 to 12 hr Total daily increments of <30 to 40 mg/d may be made every 2 days Morphine ER capsules are not indicated in opioid-naïve patients Patients who are not opioid tolerant: Start morphine ER at 30 mg daily, may adjust every 1 to 2 days Initiate at the lowest dose, 20 mg/0.8 mg once daily Opioid tolerant 2 patients: Convert current opioid to equianalgesic daily dose of morphine; reduce the calculated amount by 33-50% for initial start dose (see Table D-3) Dose may be up titrated no more frequent than every other day Morphine/naltrexone must be swallowed whole or the contents of the capsules sprinkled on apple sauce; crushing, dissolving, or chewing pellets may cause a fatal overdose (particularly in the opioid-naïve patient) and the absorption of naltrexone could increase the risk of precipitating withdrawal in opioid tolerant patients Morphine/naltrexone: If once daily results in inadequate analgesia, may switch to twice daily dosing February 2017 Page 94 of 198

8 Dose change increments: May increase to 20 mg (tablets) or 18 mg (capsules) every 12 hr after 1 or 2 days; thereafter, the total daily dose may be increased by 25-50% of the current dose every 1 or 2 days ER tablets are not bioequivalent to ER capsules; 10 mg oxycodone HCl (ER tablet) = 9 mg oxycodone base (ER capsule) Steady state achieved with tablets or capsules in 24 to 36 hr with repeat dosing Elderly: Plasma concentrations of oxycodone are increased ~15% in the elderly; however, usual dosing and dosing intervals may be appropriate Patients with renal dysfunction: Plasma concentrations of oxycodone are increased ~50% in patients with CrCl <60 ml/min; dose conservatively and adjust according to clinical situation Patients with hepatic dysfunction: Reduce initial dose to 1/3 to 1/2 of the usual dose and monitor closely Recommended for patients who experience intolerable, unmanageable adverse effects to long- acting morphine Both ER tablets and ER capsules have abuse deterrent labeling related to resistance to abuse by intranasal and intravenous means ER tablets should be swallowed whole, not broken, chewed, or crushed ER capsules may be opened and sprinkled on soft food or administered via feeding tube Oxycodone ER Tablets available in 10, 15, 20, 30, 40, 60, and 80 mg strengths for every 12 hr Capsules available in 9, 13.5, 18, 27 and 36 mg strengths for every 12 hr 10 mg (tablets) or 9 mg (capsules) orally every 12 hr Opioid tolerant.2 patients: Convert current opioid to equianalgesic daily dose of oxycodone ER; reduce the calculated amount by 33-50% for initial start dose (see Table D-3) February 2017 Page 95 of 198

9 The polyethylene oxide content causes the tablet to swell and become sticky when wet. This has the potential to cause obstruction of the airway or GI obstruction Steady state concentration of both components are reached within 24 hr of product initiation Elderly: Take precautions when determining the dosing amount and frequency in geriatric patients since a greater sensitivity to oxycodone may be observed in this patient population when compared to younger patients Patients with renal or hepatic dysfunction: Patients with renal dysfunction (CrCl <60 ml/min) or hepatic dysfunction should initiate therapy with 1 tablet every 12 hr and adjust as needed This long-acting/er opioid is an exception to the REMS requirements due to the relatively low amount of oxycodone contained in each tablet Oxycodone/APAP ER tablets are formulated with PEO which is responsible for its ER in addition to labeled abuse deterrent properties Patients should be instructed not to pre-soak, lick, or otherwise wet tablets prior to swallowing and to take one tablet at a time with adequate water to insure complete and immediate swallowing Oxycodone/APAP ER Available as tablets containing oxycodone 7.5 mg and APAP 325 mg for every 12 hr May initiate therapy with the standard dose of 2 tablets every 12 hr A standard, single dose consists of 2 tablets totaling 15 mg oxycodone/650 mg APAP This is the only longacting/er opioid to have an acute pain indication February 2017 Page 96 of 198

10 The polyethylene oxide content causes the tablet to swell and become sticky when wet. This has the potential to cause obstruction of the airway or GI obstruction Steady state concentration of both components are reached within 24 hr of product initiation Elderly: Take precautions when determining the dosing amount and frequency in geriatric patients since a greater sensitivity to oxycodone may be observed in this patient population when compared to younger patients Patients with renal or hepatic dysfunction: Patients with renal dysfunction (CrCl <60 ml/min) or hepatic dysfunction should initiate therapy with 1 tablet every 12 hr and adjust as needed This long-acting/er opioid is an exception to the REMS requirements due to the relatively low amount of oxycodone contained in each tablet Oxycodone/APAP ER tablets are formulated with PEO which is responsible for its ER in addition to labeled abuse deterrent properties Patients should be instructed not to pre-soak, lick, or otherwise wet tablets prior to swallowing and to take one tablet at a time with adequate water to insure complete and immediate swallowing Oxycodone/APAP ER Available as tablets containing oxycodone 7.5 mg and APAP 325 mg for every 12 hr May initiate therapy with the standard dose of 2 tablets every 12 hr A standard, single dose consists of 2 tablets totaling 15 mg oxycodone/650 mg APAP This is the only longacting/er opioid to have an acute pain indication February 2017 Page 96 of 198

11 Dose change increments: May increase by 5 to 10 mg every 12 hr every 3 to 7 days Oxymorphone ER tablets must be taken whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth Steady-state plasma levels are achieved after 3 days of multiple dose Elderly: Plasma drug levels are about 40% higher in elderly versus younger subjects; use caution, starting at the low end of dosing range and titrating slowly Patients with renal dysfunction: Bioavailability is increased by 57% in moderate impairment and by 65% in severe impairment; in patients with CrCl <50 ml/min, oxymorphone should be started with the lowest dose and titrated slowly Patients with hepatic dysfunction: Use with caution in patients with mild hepatic impairment, starting with lowest dose and titrating slowly Contraindicated in patients with moderate or severe hepatic impairment Must be taken on an empty stomach at least 1 hr before or 2 hr after a meal; food has been shown to increase peak levels of oxymorphone ER by 50% Must NOT be taken concomitantly with alcohol, which can cause highly variable effects on peak drug levels, ranging from a decrease of 50% to an increase of 270% Oxymorphone ER Tablets Available as 5, 7.5, 10, 15, 20, 30 and 40 mg tablets for every 12 hr Initiate at 5 mg every 12 hr Opioid tolerant.2 patients: Convert current opioid to equianalgesic daily dose of oxycodone; reduce the calculated amount by 33-50% for initial daily start dose (see Table D-3) February 2017 Page 97 of 198

12 Tapentadol ER Available as tablets containing 50, 100, 150, 200, or 250 mg tapentadol for twice daily dosing Tramadol ER Available as 100, 200 and 300 mg tablets for once daily In opioid-naïve and non-tolerant patients: Initiate therapy with 50 mg twice daily; use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression There are no established conversion ratios for conversion from other opioid to tapentadol ER; convert current opioid to an estimated equianalgesic daily dose of tapentadol; reduce the calculated amount by 33-50% for initial daily start dose (see Table D-3) Patients not currently on tramadol: 100 mg once daily Converting from tramadol IR: Start at 24 hr dosage equivalent rounded down to closest 100 mg increment Dose change increments: May increase dose by no more than 50 mg twice daily every 3 days Maximum daily dose: 500 mg daily Tapentadol ER tablets must be taken whole; crushing, chewing, or dissolving tablets will result in uncontrolled delivery of tapentadol and can lead to overdose or death Steady state is attained after the third dose (24 hr after the first twice daily multiple dose ) Dose change increments: May increase by 100 mg every 5 days based on analgesia and tolerability Maximum dose: 300 mg/day Elderly: No dosing adjustment needed, consider starting at lowest recommended dosage Patients with renal dysfunction: No dosage adjustment for mild or moderate renal impairment; not recommended in severe renal impairment Patients with hepatic dysfunction: Use not recommended in severe hepatic impairment Elderly: Start at low end of dosing range; use particular caution, especially in patients >75 years Renal dysfunction: Avoid use if CrCl <30 ml/min Hepatic dysfunction: Avoid use in severe hepatic impairment (Child- Pugh Class C) Must NOT be taken concomitantly with alcohol which can increase serum tapentadol concentration and cause fatal overdose Use with or within 14 days of MAOIs is contraindicated Must be swallowed whole and must not be chewed, crushed, or split See warnings and precautions under for tramadol IR (Table D-1) 1 Check local formulary for available formulations. 2 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone or equianalgesic dose of another opioid. February 2017 Page 98 of 198

Appendix D: Drug Tables

Appendix D: Drug Tables Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic

More information

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA

More information

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The

More information

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has

More information

Blueprint for Prescriber Continuing Education Program

Blueprint for Prescriber Continuing Education Program CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting

More information

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy

More information

Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty

Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS

More information

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy

More information

Collaboration for REMS Education

Collaboration for REMS Education Presented by CO*RE Collaboration for Relevant Presented Educationby CO*RE www.core-rems.org Collaboration for REMS Education www.corerems.org Collaborative for REMS Education CO*RE 2014 GENERAL DRUG INFORMATION

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,

More information

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics

Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy

More information

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be

More information

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Opioid Analgesics. Recommended starting dose for opioid-naïve patients Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote

More information

Opioid Conversions Mixture of Science and Art

Opioid Conversions Mixture of Science and Art Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

FENTANYL transdermal system, CII Initial U.S. Approval: 1968

FENTANYL transdermal system, CII Initial U.S. Approval: 1968 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FENTANYL TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for FENTANYL

More information

Fact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII

Fact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication

More information

AND ADMINISTRATION DURAGESIC

AND ADMINISTRATION DURAGESIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DURAGESIC safely and effectively. See full prescribing information for DURAGESIC. DURAGESIC (fentanyl

More information

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine

More information

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects. Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl

More information

EXTENDED RELEASE OPIOID DRUGS

EXTENDED RELEASE OPIOID DRUGS RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),

More information

Initiation, Titration & Discontinuation Guide

Initiation, Titration & Discontinuation Guide EXTENDED-RELEASE TABLETS 20, 30, 40, 60, 80*, 100*, and 120*mg *For opioid-tolerant patients only Initiation, Titration & Discontinuation Guide if not recognized and treated, and requires management according

More information

ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA

ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: Fentanyl by oral transmucosal and nasal delivery Actiq (fentanyl citrate) lozenge on a handle 200,

More information

Fighting the Good Fight: How to Convert Opioids Just Right!

Fighting the Good Fight: How to Convert Opioids Just Right! Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

XTAMPZA ER (oxycodone) extended-release capsules, for oral use, CII Initial U.S. Approval: 1950

XTAMPZA ER (oxycodone) extended-release capsules, for oral use, CII Initial U.S. Approval: 1950 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XTAMPZA ER safely and effectively. See full prescribing information for XTAMPZA ER. XTAMPZA ER (oxycodone)

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter

More information

OPIOID IR COMBO DRUGS. Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Tramadolacetaminophen

OPIOID IR COMBO DRUGS. Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Tramadolacetaminophen RATIONALE FOR INCLUSION IN PA PROGRAM Background Apadaz (benzhydrocodone-acetaminophen), codeine-acetaminophen, dihydrocodeine-caffeineacetaminophen, hydrocodone-acetaminophen, hydrocodone-ibuprofen, oxycodoneacetaminophen,

More information

Education Program for Prescribers and Pharmacists

Education Program for Prescribers and Pharmacists Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)

More information

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization

More information

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Pharmacy Medical Necessity Guidelines: Opioid Analgesics Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Long Term Care Formulary HCD - 08

Long Term Care Formulary HCD - 08 1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally

More information

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Extended-release (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1,

More information

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is

More information

Opioid Use in Serious Illness

Opioid Use in Serious Illness Opioid Use in Serious Illness Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado

More information

Fentanyl Transdermal System Page 1 of mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr Prescribing Information

Fentanyl Transdermal System Page 1 of mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr Prescribing Information HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use fentanyl transdermal system safely and effectively. See full prescribing information for fentanyl

More information

Adhere to instructions concerning administration and disposal of fentanyl transdermal system.

Adhere to instructions concerning administration and disposal of fentanyl transdermal system. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Fentanyl Transdermal System safely and effectively. See full prescribing information for Fentanyl

More information

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer

More information

TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII Initial U.S.

TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TROXYCA ER safely and effectively. See full prescribing information for TROXYCA ER. TROXYCA ER (oxycodone

More information

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1 Opioid Case Studies Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN September 29, 2016 2015 MFMER slide-1 Disclosures Relevant Financial Relationship(s) None Off Label and/or

More information

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction Pain Management in Hepatic and Renal Dysfunction Review the pharmacologic basis for medications used in pain management Identify pain medications which hshould ldbe avoided in patients with hepatic dysfunction

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

Opioid Pearls and Acute Pain Management

Opioid Pearls and Acute Pain Management Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program

More information

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain Medication Policy Manual Topic: Extendedrelease (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1, 2018 Committee Approval Date: January 19. 2018 Next Review Date: December

More information

Overview of Essentials of Pain Management. Updated 11/2016

Overview of Essentials of Pain Management. Updated 11/2016 0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.

More information

Berkshire West Area Prescribing Committee Guidance

Berkshire West Area Prescribing Committee Guidance Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next

More information

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated

More information

15 mg morphine 10 mg hydrocodone

15 mg morphine 10 mg hydrocodone Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually

More information

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)

More information

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted

More information

What is a lethal dose of oxycodone

What is a lethal dose of oxycodone Cari untuk: Cari Cari What is a lethal dose of oxycodone 25-2-2018 In people that are not tolerant of opioids, a single dose of 40 milligrams or a total daily dose of 80 milligrams of oxycodone has the

More information

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise

More information

Interprofessional Webinar Series

Interprofessional Webinar Series Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation

More information

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117

More information

VA/DoD Clinical Practice Guideline Management of Opioid Therapy for Chronic Pain

VA/DoD Clinical Practice Guideline Management of Opioid Therapy for Chronic Pain VA/DoD Clinical Practice Guideline Management of Opioid Therapy for Chronic Pain 1 Patient with chronic pain 2 3 6 4 8 10 Obtain comprehensive assessment Complete assessment of pain; Determine cause of

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPANA ER safely and effectively. See full prescribing information for OPANA ER. OPANA ER (oxymorphone

More information

Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015

Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Table 1: Physiologic changes that occur during sickle cell pain crisis 1-3 Phase Description / Complications

More information

Opioid Conversion Guidelines

Opioid Conversion Guidelines Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,

More information

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough

More information

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Pain Module. Top Ten Pain Safety Tips

Pain Module. Top Ten Pain Safety Tips Pain Module Top Ten Pain Safety Tips # 1 Monitor Your Patient s Level of Consciousness and Respiratory Status Do not depend on alarms to save your patient s life. You must perform your own assessments

More information

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics

More information

PRESCRIBING ALERT

PRESCRIBING ALERT www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP). Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the

More information

IS AVAILABLE IN 6 DOSAGE STRENGTHS1

IS AVAILABLE IN 6 DOSAGE STRENGTHS1 EMBEDA (morphine sulfate and naltrexone HCl) Extended-Release Capsules, for oral use, CII is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and

More information

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti- Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the

More information

Morphine equivalent calculator suboxone

Morphine equivalent calculator suboxone Morphine equivalent calculator suboxone Gogamz Menu Best Way To Lose 30 Pounds In 6 Months Fat Burner Waist Belt Fat Burn And Target Heart Rate how much weight would i lose calculator Fastest Fat Burner

More information

Comedy of Errors: Methadone and Buprenorphine

Comedy of Errors: Methadone and Buprenorphine Comedy of Errors: Methadone and Buprenorphine Douglas Gourlay MD, MSc, FRCP(C), DFASAM Disclosures Nothing to disclosure 2 1 Learning Objectives Explain the pharmacology of methadone and buprenorphine

More information

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Fentanyl Actavis 100 micrograms/h transdermal patch and associated names (see Annex I)

SUMMARY OF PRODUCT CHARACTERISTICS. Fentanyl Actavis 100 micrograms/h transdermal patch and associated names (see Annex I) SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fentanyl Actavis 25 micrograms/h transdermal patch and associated names (see Annex I) Fentanyl Actavis 50 micrograms/htransdermal patch

More information

BJF Acute Pain Team Formulary Group

BJF Acute Pain Team Formulary Group Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution

More information

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,

More information

10 mg hydrocodone equals how much oxycodone

10 mg hydrocodone equals how much oxycodone Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)

More information

Dose equivalent of fentanyl patch to oxycontin

Dose equivalent of fentanyl patch to oxycontin Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.

More information

Methadone Maintenance

Methadone Maintenance Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology

More information

Po dilaudid versus iv dilaudid

Po dilaudid versus iv dilaudid Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing

More information

What stronger oxycodone 15 or morphine ir 15

What stronger oxycodone 15 or morphine ir 15 What stronger oxycodone 15 or morphine ir 15 Here's the problem. I'm on Oxycodone for break through pain, and MSContin for long term pain relief. The problem is Morphine makes me too tired. Posts about

More information

Oxycontin to ms contin conversion chart

Oxycontin to ms contin conversion chart Oxycontin to ms contin conversion chart The Pink, One-Piece Wrap Style 1 ( Pink Stripe) Size - Small - Medium - Large Length (neck to base of tail) - 10 inches - 14 inches - 20 inches Width (without side.

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Matrimed, 12 micrograms/hour Transdermal patch Matrimed, 25 micrograms/hour Transdermal patch Matrimed, 50 micrograms/hour Transdermal

More information

Facts About BELBUCA (buprenorphine) Buccal Film

Facts About BELBUCA (buprenorphine) Buccal Film Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid

More information

Shining a Light on MEDs Understanding morphine equivalent dose

Shining a Light on MEDs Understanding morphine equivalent dose Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Session IV. Presenter Disclosure Information. Presenter Disclosure Information. Learning Objectives for Session IV

Session IV. Presenter Disclosure Information. Presenter Disclosure Information. Learning Objectives for Session IV 4 6pm SAFE Opioid Prescribing SPEAKERS Charles Argoff, MD, FABPM Bill McCarberg, MD, FABPM Michael Brennan, MD, FACP, FASAM Presenter Disclosure Information The following relationships exist related to

More information

Drug Use Evaluation: Short Acting Opioids (SAO)

Drug Use Evaluation: Short Acting Opioids (SAO) Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service

More information

Morphine er to oxycontin conversion

Morphine er to oxycontin conversion Morphine er to oxycontin conversion The Borg System is 100 % Morphine er to oxycontin conversion 17-4-2011 Conversion dose from Oxycontin 40mg 3x a day to morphine sulfate 15 mg?. Oxycontin vs morphine

More information

Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg

Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg TE Te Hydrocodone 10mg vs oxycodone 10 mg What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg Manufacturer of oxycodone hcl 15 mg tablet side effects

More information

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335

More information